Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, ...

LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned ...

Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days' use LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow ...

Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today ...